Studies have shown that consuming sesame seeds helps prevent allergies.

Published Date: 06 Mar 2023

Oral desensitization using crushed sesame seeds and tahini may be a safe and effective method to desensitize pediatric patients with sesame allergy...

Read Full News

Latest News

Arizona Accuses L'Oreal Of Concealing Cancer Risks Linked to Hair Relaxers

Arizona has sued L'Oreal SA and its U.S. subsidiary, alleging the cosmetics company hid evidence that its hair relaxer products could cause cancer ⁠in women, as it faces...

Pembrolizumab Benefits Persist in Cervical Cancer

After 5 years of follow-up, pembrolizumab plus chemotherapy continues to demonstrate sustained survival advantages in patients with persistent, recurrent, or metastatic cervical cancer.

Combo Therapy May Help in Systemic Autoinflammatory Diseases

Patients with systemic autoinflammatory diseases refractory to standard treatments may show clinical improvements when treated with combinations of biologics and JAK inhibitors.

Criteria for Prescribing Testosterone: Who Qualifies?

A Brazilian multidisciplinary consensus sets thresholds for the diagnosis and treatment while emphasizing symptom assessment, repeated testing, and attention to the underlying causes.

Prostate Cancer Spending Nearly Quadrupled Over 10 Years

Medicare spending on prostate cancer care rose sharply from 2012 to 2021, driven largely by increased spending on systemic therapies.

Do IL-17 Inhibitors Increase IBD Risk in HS?

A meta-analysis finds no significant increase in the risk for inflammatory bowel disease among patients with hidradenitis suppurativa treated with IL-17 inhibitors.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Latest News

Arizona has sued L'Oreal SA and its U.S. subsidiary, alleging the cosmetics company hid evidence that its hair relaxer products could cause cancer ⁠in women, as it faces...

After 5 years of follow-up, pembrolizumab plus chemotherapy continues to demonstrate sustained survival advantages in patients with persistent, recurrent, or metastatic cervical cancer.

Patients with systemic autoinflammatory diseases refractory to standard treatments may show clinical improvements when treated with combinations of biologics and JAK inhibitors.

A Brazilian multidisciplinary consensus sets thresholds for the diagnosis and treatment while emphasizing symptom assessment, repeated testing, and attention to the underlying causes.

Medicare spending on prostate cancer care rose sharply from 2012 to 2021, driven largely by increased spending on systemic therapies.

A meta-analysis finds no significant increase in the risk for inflammatory bowel disease among patients with hidradenitis suppurativa treated with IL-17 inhibitors.

News All Time

Better Survival Seen With Spartalizumab Addition in Melanoma

More than 500 adults with BRAF V600-mutant cutaneous melanoma were randomly assigned to receive either intravenous spartalizumab plus oral dabrafenib and trametinib or oral dabrafenib and trametinib.

Advances in MCC: Q&A With Paul Nghiem, MD, PhD

Paul Nghiem, MD, PhD, a global expert in Merkel cell carcinoma, spoke with Medscape Dermatology about recent findings and trends in MCC care and research, as well as a look into the future.

Sofpironium Gel Safety Confirmed in Real-World Use

Real-world surveillance shows adverse events consistent with the known safety profile of sofpironium gel for excessive underarm sweating.

Taking Steps to Reduce Disparities in Women’s Rheumatic Care

Women acquire rheumatic and musculoskeletal diseases more frequently than men. Rheumatologists are working to improve disparities — and overall care — for their female patients.

Experts Say One Menopause Treatment Cannot Fit Every Woman

Experts emphasise individualised menopause care, with treatment decisions guided by symptoms, health risks, preferences, and changing needs rather than a fixed approach.

Sleepmaxxing: Are Popular Sleep Hacks Evidence-Based?

Sleepmaxxing practices vary in their evidence, with some routines supported by research, while others lack proven benefits or may worsen sleep problems.

Vitamin D Deficiency Needs a Tailored Approach

Vitamin D deficiency may improve in summer, but experts say many patients still need individualized treatment, especially if sun exposure is limited.

Diclofenac Did Not Reduce Chemo-Induced Hand-Foot Syndrome

Researchers assess hand-foot syndrome in patients receiving diclofenac who are scheduled to receive capecitabine-based chemotherapy for cancer.

Upadacitinib Effective in PsA After TNF Inhibitor Failure

Upadacitinib is linked to effective clinical responses in patients with psoriatic arthritis who have received prior TNF inhibitor therapy.

Does Tapering TNF Inhibitors Maintain Low Disease Activity?

In patients with psoriatic arthritis and axial spondyloarthritis, a treat-to-target tapering strategy for TNF inhibitors may maintain low disease activity for up to 2 years.

FDA Approves First Oral Drug for Dermatomyositis in Adults

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

Early Step-Down Safe, Cost-Effective in Stable Candidiasis

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

China Approves J&J Psoriasis Pill Icotyde, Says Drugmaker

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar Lichen Sclerosus Affects 1 in 700 US Women

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib Controls Skin Disease in Dermatomyositis

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

Recommended News For You

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

Clinical trial is testing whether heavy lifting could combat cancer side effects

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

A healthier lifestyle after bowel screening shown to prevent bowel cancer

Recommended Articles For You

Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy 

Hematopoietic Microenvironment Rejuvenation Through Cellular Architecture Remodeling 

Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions 

Engineered Hematopoietic Cells for Targeted Correction of Abnormal Blood-Cell Production 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sevabertinib Approved for First-Line Mutated NSCLC

2.

Top 10 questions about breast cancer answered

3.

Inadvertent lung cancer screening results are discussed in a new study.

4.

United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.

5.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

1.

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain

2.

An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025

3.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

4.

A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer

5.

CA-125 Test: Why It's Important for Women's Health and Early Detection of Ovarian Cancer

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

5.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot